The FDA published more than 200 letters that it sent to companies when it rejected their medicines, but the letters came with a caveat.

The U.S. Food and Drug Administration on Thursday published more than 200 of its so-called complete response letters to drugmakers, a significant move to increase transparency of the agency's work.

Investors have long asked the FDA to share its reasons for rejecting drugs, arguing that companies can use the agency’s silence on the matter to mislead the market.

The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving ...

The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...

The U.S. FDA publishes over 200 complete response letters to enhance transparency within the agency. Read more here.

A viral rejection email accidentally included AI instructions—revealing how some companies really reject job seekers.

Before America had the Declaration of Independence, much less the Constitution, the nation had the Postal Service. Before ...

I’m surprised that Baylor still matters that much to me given its ongoing ambivalence, at best, and lack of Christian love, ...

Rather than an outright ban, a reader proposes dog-walking loops around farms — offering healthy exercise for dogs and their ...

Despite a rejection on their first offer, the residents of two mobile home parks and their representatives will continue to ...

A free account provides you access to a limited number of free articles each month, plus newsletters, job postings, salary ...